Seres Therapeutics Inc Cash Flow Conversion Efficiency
Seres Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has a cash flow conversion efficiency ratio of -0.648x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.39 Million) by net assets ($34.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Seres Therapeutics Inc (2012–2025)
Cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2025. This chart illustrates how Seres Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Seres Therapeutics Inc (MCRB) share price today for real-time trading data and today's change.
Seres Therapeutics Inc Cash Flow Conversion Ratio Explained
Seres Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Seres Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seres Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Seres Therapeutics Inc (MCRB) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AJ Advance Technology Public Company Limited
BK:AJA
|
-0.019x |
|
ATA Creativity Global
NASDAQ:AACG
|
0.007x |
|
BOXABL Inc.
NASDAQ:BXBL
|
-0.230x |
|
Asia Technology Co Ltd
KQ:050860
|
-0.028x |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
0.051x |
|
SCI Electric Public Company Limited
BK:SCI
|
0.031x |
|
Gensight Biologics SA
PA:SIGHT
|
0.260x |
|
INSPIREMD 1/18 DL-0001
F:II2
|
-0.169x |
Annual Cash Flow Conversion Efficiency for Seres Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2025. Review Seres Therapeutics Inc (MCRB) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.22 Million | $1.12 Million | 0.025x | +100.23% |
| 2024-12-31 | $13.78 Million | $-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | $-44.86 Million | $-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | $10.78 Million | $-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | $131.51 Million | $6.69 Million | 0.051x | +109.49% |
| 2020-12-31 | $174.75 Million | $-93.61 Million | -0.536x | -133.83% |
| 2019-12-31 | $-48.32 Million | $-76.52 Million | 1.583x | +21.04% |
| 2018-12-31 | $-48.05 Million | $-62.85 Million | 1.308x | +205.14% |
| 2017-12-31 | $60.70 Million | $-75.52 Million | -1.244x | -475.73% |
| 2016-12-31 | $132.63 Million | $43.92 Million | 0.331x | +266.53% |
| 2015-12-31 | $205.39 Million | $-40.84 Million | -0.199x | -151.30% |
| 2014-12-31 | $-26.72 Million | $-10.36 Million | 0.388x | +104.60% |
| 2013-12-31 | $631.00K | $-5.32 Million | -8.433x | -1733.56% |
| 2012-12-31 | $6.36 Million | $-2.92 Million | -0.460x | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more